Arcus Biosciences RCUS
NYSE RCUS
$25.67 +0.66 (+2.62%)
As of: Sep 29, 2026 · 3:59 PM EDT

Arcus Biosciences (RCUS) EV to EBITDA (2021 - 2022)

Updated

Arcus Biosciences' EV to EBITDA was 10.36 in Q3 2022, up 14.5% from the prior quarter.

Analysis

Arcus Biosciences (RCUS) EV to EBITDA (2021 - 2022) Analysis & Trends

On a trailing twelve-month basis, Arcus Biosciences' EV to EBITDA was -25.08 through Sep 30, 2022; for FY2021, it was 40.79.

  • Quarterly EV to EBITDA has moved between 9.04 (Q2 2022) and 40.79 (Q4 2021) over five years.
  • Per Business Quant data, RCUS's EV to EBITDA in the three quarters before Q3 2022 was 9.04 (Q2 2022), 16.37 (Q1 2022) and 40.79 (Q4 2021).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn
10 Arcus Biosciences 3.18 Bn -157.19 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2022 10.36
Jun 30, 2022 9.04
Mar 31, 2022 16.37
Dec 31, 2021 40.79
API Access

Arcus Biosciences EV to EBITDA API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ev-to-ebitda&ticker=RCUS&period=max&api_key=YOUR_API_KEY